These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

522 related items for PubMed ID: 23642545

  • 1. Combination of zoledronic Acid and targeted therapy is active but may induce osteonecrosis of the jaw in patients with metastatic renal cell carcinoma.
    Smidt-Hansen T, Folkmar TB, Fode K, Agerbaek M, Donskov F.
    J Oral Maxillofac Surg; 2013 Sep; 71(9):1532-40. PubMed ID: 23642545
    [Abstract] [Full Text] [Related]

  • 2. Prognostic significance of bone metastases and bisphosphonate therapy in patients with renal cell carcinoma.
    McKay RR, Lin X, Perkins JJ, Heng DY, Simantov R, Choueiri TK.
    Eur Urol; 2014 Sep; 66(3):502-9. PubMed ID: 24613250
    [Abstract] [Full Text] [Related]

  • 3. Is administration of trastuzumab an independent risk factor for developing osteonecrosis of the jaw among metastatic breast cancer patients under zoledronic acid treatment?
    Pilanci KN, Alco G, Ordu C, Sarsenov D, Celebi F, Erdogan Z, Agacayak F, Ilgun S, Tecimer C, Demir G, Eralp Y, Okkan S, Ozmen V.
    Medicine (Baltimore); 2015 May; 94(18):e671. PubMed ID: 25950681
    [Abstract] [Full Text] [Related]

  • 4. Clinical study evaluating the effect of bevacizumab on the severity of zoledronic acid-related osteonecrosis of the jaw in cancer patients.
    Lescaille G, Coudert AE, Baaroun V, Ostertag A, Charpentier E, Javelot MJ, Tolédo R, Goudot P, Azérad J, Berdal A, Spano JP, Ruhin B, Descroix V.
    Bone; 2014 Jan; 58():103-7. PubMed ID: 24120382
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. A contemporary update on rates and management of toxicities of targeted therapies for metastatic renal cell carcinoma.
    Alasker A, Meskawi M, Sun M, Ismail S, Hanna N, Hansen J, Tian Z, Bianchi M, Perrotte P, Karakiewicz PI.
    Cancer Treat Rev; 2013 Jun; 39(4):388-401. PubMed ID: 23317510
    [Abstract] [Full Text] [Related]

  • 8. Osteonecrosis of the jaw in patients with cancer who received zoledronic acid and bevacizumab.
    Francini F, Pascucci A, Francini E, Miano ST, Bargagli G, Ruggiero G, Petrioli R.
    J Am Dent Assoc; 2011 May; 142(5):506-13. PubMed ID: 21531932
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Replacing zoledronic acid with denosumab is a risk factor for developing osteonecrosis of the jaw.
    Higuchi T, Soga Y, Muro M, Kajizono M, Kitamura Y, Sendo T, Sasaki A.
    Oral Surg Oral Med Oral Pathol Oral Radiol; 2018 Jun; 125(6):547-551. PubMed ID: 29574058
    [Abstract] [Full Text] [Related]

  • 11. Osteonecrosis of the Jaw in Patients Receiving Bone-Targeted Therapies: An Overview--Part I.
    Turner B, Drudge-Coates L, Ali S, Pati J, Nargund V, Ali E, Cheng L, Wells P.
    Urol Nurs; 2016 Jun; 36(3):111-6, 154. PubMed ID: 27501591
    [Abstract] [Full Text] [Related]

  • 12. A Systematic Review and Meta-analysis Comparing the Effectiveness and Adverse Effects of Different Systemic Treatments for Non-clear Cell Renal Cell Carcinoma.
    Fernández-Pello S, Hofmann F, Tahbaz R, Marconi L, Lam TB, Albiges L, Bensalah K, Canfield SE, Dabestani S, Giles RH, Hora M, Kuczyk MA, Merseburger AS, Powles T, Staehler M, Volpe A, Ljungberg B, Bex A.
    Eur Urol; 2017 Mar; 71(3):426-436. PubMed ID: 27939075
    [Abstract] [Full Text] [Related]

  • 13. Osteonecrosis of the jaws in patients assuming bisphosphonates and sunitinib: two case reports.
    Agrillo A, Nastro Siniscalchi E, Facchini A, Filiaci F, Ungari C.
    Eur Rev Med Pharmacol Sci; 2012 Jul; 16(7):952-7. PubMed ID: 22953645
    [Abstract] [Full Text] [Related]

  • 14. A 5-year retrospective longitudinal study on the incidence and the risk factors of osteonecrosis of the jaws in patients treated with zoledronic acid for bone metastases from solid tumors.
    Manfredi M, Mergoni G, Goldoni M, Salvagni S, Merigo E, Meleti M, Vescovi P.
    Med Oral Patol Oral Cir Bucal; 2017 May 01; 22(3):e342-e348. PubMed ID: 28390132
    [Abstract] [Full Text] [Related]

  • 15. Positive effects of zoledronate on skeletal-related events in patients with renal cell cancer and bone metastases.
    Tunn UW, Stenzl A, Schultze-Seemann W, Strauss A, Kindler M, Miller K, Wirth MP, Zantl N, Schulze M, May C, Ruebel A, Birkholz K, Gruenwald V.
    Can J Urol; 2012 Jun 01; 19(3):6261-7. PubMed ID: 22704310
    [Abstract] [Full Text] [Related]

  • 16. Targeted Therapy for Metastatic Renal Cell Carcinoma.
    Afriansyah A, Hamid AR, Mochtar CA, Umbas R.
    Acta Med Indones; 2016 Oct 01; 48(4):335-347. PubMed ID: 28143997
    [Abstract] [Full Text] [Related]

  • 17. Sunitinib, pazopanib or sorafenib for the treatment of patients with late relapsing metastatic renal cell carcinoma.
    Santoni M, Conti A, Porta C, Procopio G, Sternberg CN, Basso U, De Giorgi U, Bracarda S, Rizzo M, Ortega C, Massari F, Iacovelli R, Derosa L, Masini C, Milella M, Di Lorenzo G, Atzori F, Pagano M, Buti S, De Vivo R, Mosca A, Rossi M, Paglino C, Verzoni E, Cerbone L, Muzzonigro G, Falconi M, Montironi R, Burattini L, Santini D, Cascinu S.
    J Urol; 2015 Jan 01; 193(1):41-7. PubMed ID: 25046616
    [Abstract] [Full Text] [Related]

  • 18. Improvement in survival end points of patients with metastatic renal cell carcinoma through sequential targeted therapy.
    Calvo E, Schmidinger M, Heng DY, Grünwald V, Escudier B.
    Cancer Treat Rev; 2016 Nov 01; 50():109-117. PubMed ID: 27664394
    [Abstract] [Full Text] [Related]

  • 19. Bisphosphonates and vascular endothelial growth factor-targeted drugs in the treatment of patients with renal cell carcinoma metastatic to bone.
    Vrdoljak E, Rini B, Schmidinger M, Omrčen T, Torday L, Szczylik C, Sella A.
    Anticancer Drugs; 2013 Jun 01; 24(5):431-40. PubMed ID: 23511427
    [Abstract] [Full Text] [Related]

  • 20. Signaling inhibitors in metastatic renal cell carcinoma.
    Escudier B.
    Cancer J; 2008 Jun 01; 14(5):325-9. PubMed ID: 18836338
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 27.